Comparative Pharmacology
Head-to-head clinical analysis: ADVIL DUAL ACTION WITH ACETAMINOPHEN versus KETOROLAC TROMETHAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL DUAL ACTION WITH ACETAMINOPHEN versus KETOROLAC TROMETHAMINE.
ADVIL DUAL ACTION WITH ACETAMINOPHEN vs KETOROLAC TROMETHAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Acetaminophen is an analgesic and antipyretic whose mechanism is not fully understood but involves inhibition of cyclooxygenase in the central nervous system and modulation of the endocannabinoid system.
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing pain and inflammation.
One caplet (ibuprofen 250 mg and acetaminophen 500 mg) orally every 8 hours while symptoms persist; maximum: 3 caplets per day.
10 mg orally every 4-6 hours, not to exceed 40 mg per day; or 15-30 mg intramuscularly or intravenously every 6 hours, not to exceed 120 mg per day (maximum 60 mg for single dose).
None Documented
None Documented
Ibuprofen: 2-4 hours; Acetaminophen: 2-3 hours. Clinical context: Short half-lives require dosing every 6-8 hours. Extended half-life in overdose (acetaminophen >4 hours indicates toxicity).
Terminal half-life is 5-6 hours in young adults, prolonged to 9-10 hours in elderly patients (≥65 years) and up to 12-15 hours in renal impairment (CrCl <30 mL/min). Context: q6h dosing interval recommended; accumulation risk in elderly/renal impairment.
Ibuprofen: renal (90% as metabolites and conjugates, <10% unchanged); Acetaminophen: renal (85% as sulfate and glucuronide conjugates, 4% unchanged, 9% as cysteine and mercapturic acid conjugates; minor biliary).
Primarily renal excretion: ~92% of dose excreted in urine as parent drug (60%) and metabolites (p-hydroxyketorolac, conjugated forms). Fecal excretion accounts for ~6%. Biliary excretion is minimal.
Category C
Category D/X
NSAID/Analgesic Combination
NSAID